Click on image to view larger version.

Figure 1 Percentage of patients responding to levosimendan or placebo/vehicle or dobutamine (DO) by achieving predefined hemodynamic responses (stroke volume [SV], pulmonary capillary wedge pressure [PCWP]) at 23 h to 24 h, or requiring dose reduction for specified hemodynamic changes at any time during infusion, or having adverse dose-limiting events (DLE).